HK2 and hepatocellular carcinoma: The expression of HK2, the prevalent isoform in HCC, is associated with reduced survival in HCC patients [39], and, accordingly, HK2 inhibition dampens glycolysis in favor of OXPHOS, relieving the tumor phenotype [40].